The North America immunoglobulin market is anticipated to register with a CAGR of 6.95% across the forecasted years of 2022 to 2030, reaching a revenue share of $11388.60 million by 2030.

NORTH AMERICA IMMUNOGLOBULIN MARKET FORECAST 2022-2030

North America Immunoglobulin Market by Product (IGG, IGA, IGM, IGE, IGD) Market by Mode of Delivery (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Intramuscular Immunoglobulin) Market by Application (Hypogamma Globulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITB), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Other Applications) Market by Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Other Distribution Channels) Market by End-user (Hospitals & Clinics, Homecare) by Geography

Request free sample

Report Summary

The market growth of the region is supplemented by key drivers like the high prevalence of different types of diseases, the growth in product approvals by the United States Food and Drug Administration (FDA), and the presence of key industry players. However, the North America immunoglobulin market is likely to be hindered by the changing geo-political scenario as well as strict government policies and regulations.

To know more about this report, request a free sample copy

The North America immunoglobulin market growth evaluation includes the assessment of the United States and Canada. The increasing incidence of various diseases is a key factor expected to propel the market’s growth in the United States. According to the data issued by the National Institutes of Health, nearly 500,000 people in the country are diagnosed with over 200 types of primary immunodeficiency disorders. Moreover, the growth in primary as well as acquired immunodeficiency diseases, including AIDS and X-linked hypogammaglobulinemia, is set to facilitate the demand for immunoglobulin therapies in the United States over the upcoming years.

On the other hand, the introduction of new intravenous immunoglobulin therapies and the rise in FDA approvals are likely to further promote the market growth of the country during the forecast period. In this regard, ADMA Biologics Inc, a United States-based biopharmaceutical firm, received the Prior Approval Supplement (PAS) by the FDA for BIVIGAM (IVIG, 10% liquid) in 2019. BIVIGAM is mainly utilized for treating primary humoral immunodeficiency. Likewise, in 2017, CSL Behring, headquartered in the United States, received approval from the FDA for its novel intravenous immunoglobulin drug, Privigen. Therefore, the abovementioned factors are expected to augment the immunoglobulin market growth in North America during the forecast years.

The North America immunoglobulin market is segmented into product, mode of delivery, application, distribution channel, and end-user. The product segment is further classified into IgG, IgA, IgM, IgE, and IgD. Immunoglobulin A (IgA), also termed sIgA in its secretory form, is a type of antibody that plays a critical role in mucous membranes’ immune function. Moreover, the immunoglobulin A produced in association with mucosal membranes is relatively higher compared to other antibodies combined. In absolute terms, nearly three to five grams are secreted into the intestinal lumen daily, representing around 15% of the overall immunoglobulins produced within the body.

In contrast, immunoglobulin M (IgM) is an isotype of antibodies produced by vertebrates. While immunoglobulin M is the largest antibody, it is also the first antibody to appear in response to initial antigen exposure. Also, immunoglobulin M antibody is generated as a B cell membrane-bound monomer, in addition to a secreted pentamer.

Some of the leading companies operating in the North America immunoglobulin market include CSL Behring, ADMA Biologics, Pfizer Inc, etc.

With its headquarters in the United States, ADMA Biologics is a biopharmaceutical company that manufactures, develops, and aims to commercialize specialty plasma-based biologics for treating as well as preventing primary immune deficiency disease and other infectious disorders.

The company is also involved in the commercialization and development of human plasma and plasma-derived therapeutics.

Report Synopsis

Report Scope	Details
Market Forecast Years	2022-2030
Base Year	2021
Market Historical Years	2018-2021
Forecast Units	Revenue ($ Million)
Segments Analyzed	Product, Mode of Delivery, Application, Distribution Channel, End-User
Countries Analyzed	The United States and Canada.
Companies Analyzed	Biotest AG, China Biologic Products Inc, Grifols SA, LFB Group, CSL Behring, Kedrion, Octapharma AG, Takeda Pharmaceutical Company Limited, Bio Products Laboratory, Shanghai RAAS Blood Products Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, ADMA Biologics, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Kamada Ltd

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.

RESEARCH SCOPE & METHODOLOGY
- STUDY OBJECTIVES
- SCOPE OF STUDY
- METHODOLOGY
- ASSUMPTIONS & LIMITATIONS
EXECUTIVE SUMMARY
- MARKET SIZE & ESTIMATES
- MARKET OVERVIEW
MARKET DYNAMICS
- KEY DRIVERS
  - GROWTH IN GERIATRIC POPULATION
  - PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
  - INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
- KEY RESTRAINTS
  - HIGH COST OF THERAPY
  - HIGH RISK OF SIDE EFFECTS

KEY ANALYTICS
- IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
- KEY MARKET TRENDS
- PORTER’S FIVE FORCES ANALYSIS
  - BUYERS POWER
  - SUPPLIERS POWER
  - SUBSTITUTION
  - NEW ENTRANTS
  - INDUSTRY RIVALRY
- OPPORTUNITY MATRIX
- VENDOR LANDSCAPE
- KEY BUYING CRITERIA
  - SOURCE
  - APPLICATION
  - EPITOPE
  - VALIDATION
- REGULATORY FRAMEWORK
MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE
GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED STATES
    - CANADA

COMPETITIVE LANDSCAPE
- KEY STRATEGIC DEVELOPMENTS
  - MERGERS & ACQUISITIONS
  - PRODUCT LAUNCHES & DEVELOPMENTS
  - PARTNERSHIPS & AGREEMENTS
  - BUSINESS EXPANSIONS & DIVESTITURES
- COMPANY PROFILES
  - ADMA BIOLOGICS
  - BIO PRODUCTS LABORATORY
  - BIOTEST AG
  - CHINA BIOLOGIC PRODUCTS INC
  - CSL BEHRING
  - GRIFOLS SA
  - KAMADA LTD
  - KEDRION BIOPHARMA
  - LFB GROUP
  - OCTAPHARMA AG
  - PFIZER INC
  - SANQUIN PLASMA PRODUCTS BV
  - SHANGHAI RAAS BLOOD PRODUCTS CO LTD
  - SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
  - TAKEDA PHARMACEUTICAL COMPANY LIMITED

LIST OF TABLES

TABLE 1: MARKET SNAPSHOT – IMMUNOGLOBULIN

TABLE 2: REGULATORY FRAMEWORK

TABLE 3: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 5: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 7: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 15: LEADING PLAYERS OPERATING IN NORTH AMERICA IMMUNOGLOBULIN MARKET

TABLE 16: LIST OF MERGERS & ACQUISITIONS

TABLE 17: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 18: LIST OF PARTNERSHIPS & AGREEMENTS

TABLE 19: LIST OF BUSINESS EXPANSIONS & DIVESTITURES

LIST OF FIGURES

FIGURE 1: KEY MARKET TRENDS

FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

FIGURE 3: OPPORTUNITY MATRIX

FIGURE 4: VENDOR LANDSCAPE

FIGURE 5: KEY BUYING CRITERIA

FIGURE 6: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

FIGURE 7: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

FIGURE 8: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

FIGURE 9: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

FIGURE 10: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

FIGURE 11: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

FIGURE 12: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

FIGURE 13: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 14: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 15: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

FIGURE 16: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

FIGURE 17: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

FIGURE 18: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 19: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 20: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

FIGURE 21: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

FIGURE 22: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

FIGURE 23: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

FIGURE 24: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

FIGURE 25: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

FIGURE 26: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 27: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

FIGURE 28: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 29: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

FIGURE 30: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

FIGURE 31: NORTH AMERICA IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 32: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

FIGURE 33: NORTH AMERICA IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

FIGURE 34: NORTH AMERICA IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 35: UNITED STATES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: CANADA IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

SEGMENTATION

GEOGRAPHICAL ANALYSIS
- NORTH AMERICA
  - MARKET SIZE & ESTIMATES
  - KEY GROWTH ENABLERS
  - KEY CHALLENGES
  - KEY PLAYERS
  - COUNTRY ANALYSIS
    - UNITED STATES
    - CANADA

MARKET BY PRODUCT
- IGG
- IGA
- IGM
- IGE
- IGD
MARKET BY MODE OF DELIVERY
- INTRAVENOUS IMMUNOGLOBULIN
- SUBCUTANEOUS IMMUNOGLOBULIN
- INTRAMUSCULAR IMMUNOGLOBULIN
MARKET BY APPLICATION
- HYPOGAMMA GLOBULINEMIA
- CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
- PRIMARY IMMUNODEFICIENCY DISEASES
- MYASTHENIA GRAVIS
- MULTIFOCAL MOTOR NEUROPATHY
- IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
- INFLAMMATORY MYOPATHIES
- SPECIFIC ANTIBODY DEFICIENCY
- GUILLAIN-BARRE SYNDROME
- OTHER APPLICATIONS
MARKET BY DISTRIBUTION CHANNEL
- HOSPITAL PHARMACY
- SPECIALTY PHARMACY
- OTHER DISTRIBUTION CHANNELS
MARKET BY END-USER
- HOSPITALS & CLINICS
- HOMECARE